[Hepatitis B immunization of patients with inherited bleeding disorders: personal experiences].
Hepatitis B immunization of patients with inherited bleeding disorders: personal experiences Hepatitis B vaccination was initiated in 55 patients with inherited bleeding disorders in 1994-2009. Patients received three doses of subcutaneous recombinant vaccine containing 20 mg HBsAg (hepatitis B surface antigen) at 0, 1 and 6 months. Blood samples were obtained at the starting of vaccination, 1-3 months after immunization, and biennially thereafter. The samples were tested for HBsAg, hepatitis B surface and core antibodies (anti-HBs, anti-HBc). Protective anti-HBs level (≥10 IU/l) after immunization was proved in 50 of 51 patients (98 %). Waning of protective anti-HBs antibodies was detected in 4 % and 24 % of patients within 5 and 10 years after vaccination. No HBsAg carrier status or anti-HBc seroconversion were detected. Subcutaneous vaccination against hepatitis B provides long-term protection in patients with inherited bleeding disorders.
Roznovský
L
L
Department of Infectious Diseases, University Hospital Ostrava, Ostrava, Czech Republic. ludek.roznovsky@fnspo.cz
Orságová
I
I
Tvrdík
J
J
Blazek
B
B
Kabieszová
L
L
Lochman
I
I
Kloudová
A
A
Zjevíková
A
A
Hozáková
L
L
D000293:Adolescent; D000328:Adult; D025861:Blood Coagulation Disorders, Inherited; D002648:Child; D002675:Child, Preschool; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D007114:Immunization; D007223:Infant; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D014614:Vaccines, Synthetic; D055815:Young Adult
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic